Skip to Main Content

Paper Details

A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
0
2023
Carfilzomib, cardiovascular, carfilzomib, melphalan, multiple myeloma, myeloma, patient, patients, stem cell
Author NameAffiliation
Rafael FonsecaMayo Clinic Rochester
Sundararajan Vincent RajkumarMayo Clinic Rochester
  • 1 - 2

Datasets

Release 1.2